



PATENT  
Customer No. 22,852  
Attorney Docket No. 04853.0085

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
OGATA et al. ) Group Art Unit: 1646  
Application No.: 10/019,501 )  
Filed: December 31, 2001 )  
For: AGENT FOR AMELIORATING )  
LOW VASOPRESSIN LEVEL )

Commissioner for Patents  
Washington, DC 20231

Sir:

RECEIVED  
MAR 19 2003  
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

PATENT  
Customer No. 22,852  
Application No.: 10/019,501  
Attorney Docket No. 04853.0085

documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: March 18, 2003

By: Rebecca M. McNeill  
Rebecca M. McNeill  
Reg. No. 43,796

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

MAR 18 2003



## INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

RECEIVED  
M A R 1 8 2 0 0 3  
TECH CENTER 1800/2800

Atty. Docket No.	04853.0085	Appln. No.	10/019,501
Applicant	Etsuro OGATA et al.		
Filing Date	December 31, 2001	Group:	1646

U.S. PATENT DOCUMENTS							
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate	
	5,626,845	05/06/1997	Yoneda et al.	424	145.1		
	5,993,817	11/30/1999	Yoneda et al.	424	158.1		
	5,849,695	12/15/1998	Cohen et al.	514	12		
	5,217,896	06/08/1993	Kramer et al.	435	240.27		
	4,771,124	09/13/1988	Rosenblatt et al.	530	324		
	09/423,800		Sato et al.	530	388.85	11/12/1999	
	09/720,326		Sato et al.			12/22/2000	

## FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
·	WO 89/11297	11/30/89	WIPO			
·	WO 89/11298	11/30/89	WIPO			
·	WO 90/07861	07/26/90	WIPO			
·	WO 91/16928	11/14/91	WIPO			
·	WO 92/17602	10/15/92	WIPO			
·	WO 93/13133	07/08/93	WIPO			Abstract
·	WO 94/11523	05/26/94	WIPO			
·	WO 96/22790	08/01/96	WIPO			
·	WO 96/03437	02/08/96	WIPO			
·	WO 96/39184	02/08/96	WIPO			
·	WO 96/33735	10/31/96	WIPO			
·	WO 96/26737	09/06/96	WIPO			
·	WO 98/13388	04/02/98	WIPO			
·	WO 98/51329	11/19/98	WIPO			
·	WO 99/57139	11/11/99	WIPO			
·	WO 00/00219	01/06/00	WIPO			Abstract

MAR 18 2003



OMB No. 0651-0011

## INFORMATION DISCLOSURE CITATION

RECEIVED  
TECH CENTER 1600/2600  
MAR 18 2003  
1600/2600

Atty. Docket No.	04853.0085	Appln. No.	10/019,501
Applicant	Etsuro OGATA et al.		
Filing Date	December 31, 2001	Group:	1646

## FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
.	EP 0 293 130	11/30/88	Europe			
.	EP 0293 158	11/30/88	Europe			
.	EP 0 449 405	10/02/91	Europe			
.	EP 0 811 383	12/10/97	Europe			
.	EP 0 878 201 A1	11/18/98	Europe			
.	EP 1 004 313 A1	05/31/00	Europe			
.	EP 1 090 643 A1	04/11/01	Europe			
.	JP 4-502408	05/07/92	Japan			Abstract
.	JP 11-80025	03/23/1999	Japan			Abstract
.	JP 11-222440	08/17/1999	Japan			Abstract
.	JP 2000-080100	03/21/2000	Japan			Abstract

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Abou-Samra et al., Expression Cloning of a Common Receptor for Parathyroid Hormone and Parathyroid Hormone-Related Peptide from Rat Osteoblast-Like Cells: A Single Receptor Stimulates Intracellular Accumulation of Both cAMP and Inositol Trisphosphates and Increases Intracellular Free Calcium, <i>Proceedings of the National Academy of Sciences</i> , 89:2732-2736 (1992).
	Baba, PTH/PTHrP, <i>Clinical Calcium</i> , 5:97-101 (1995) (English Translation).
	Beck, et al., Lipolytic Factors Associated with Murine and Human Cancer Cachexia, <i>Journal of the National Cancer Institute</i> , 82:1922-1926 (1990).
	Belyavsky et al., PCR-Based cDNA Library Construction: General cDNA Libraries at the Level of a Few Cells, <i>Nucleic Acids Research</i> , 17:2919-2933 (1989).
	Burtis, Parathyroid Hormone-Related Protein: Structure, Function, and Measurement, <i>Clinical Chemistry</i> , 38:2171-2183 (1992).
	Carter et al., Humanization of an Anti-p185 <sup>HER2</sup> Antibody for Human Cancer Therapy, <i>Proceedings of the National Academy of Sciences</i> , 89:4285-4289 (1992).
	Chirgwin et al., Isolation of Biologically Active Ribonucleic Acid From Sources Enriched in Ribonuclease, <i>Biochemistry</i> , 18:5294-5299 (1979).
	Chomczynski et al., Single-Step Method of RNA Isolation By Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction, <i>Analytical Biochemistry</i> , 162:156-159 (1987).

MAR 18 2003  
PATENT & TRADEMARK OFFICE  
U.S. GOVERNMENT

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	04853.0085	Appn. No.	10/019,501
Applicant	Etsuro OGATA et al.		
Filing Date	December 31, 2001	Group:	1646

RECEIVED  
MAY 19 2003  
TECH CENTER 1600/2000

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Chothia, Canonical Structures for the Hypervariable Regions of Immunoglobulins, <i>Journal of Molecular Biology</i> , 196:901-917 (1987).
	Co et al., Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen, <i>The Journal of Immunology</i> , 148:1149-1154 (1992).
	Co et al., Humanized Antibodies for Antiviral Therapy, <i>Proceedings of the National Academy of Sciences</i> , 88:2869-2873 (1991).
	Coleman et al., Biochemical Mechanisms of Parathyroid Hormone Action, <i>The Parathyroids, Basic and Clinical Concepts</i> , 239-258 (1994).
	Cuisinier et al., Mechanisms That Generate Human Immunoglobulin Diversity Operate From the 8 <sup>th</sup> Week of Gestation in Fetal Liver, <i>European Journal of Immunology</i> , 23:110-118 (1993).
	Dariavach et al., Human Immunoglobulin C <sub>λ</sub> 6 Gene Encodes the Kern <sup>+</sup> Oz λ Chain and C <sub>λ</sub> 4 and C <sub>λ</sub> 5 are Pseudogenes, <i>Proceedings of the National Academy of Sciences</i> , 84:9074-9078 (1987).
	Deftos et al., Utilization of a Potentially Universal Downstream Primer in the Rapid Identification and Characterization of Vλ Genes From Two New Human Vλ Families, <i>Scandinavian Journal of Immunology</i> , 39:95-103 (1994).
	de St. Groth, et al., Production of Monoclonal Antibodies: Strategy and Tactics, <i>Journal of Immunological Methods</i> , 35:1-21 (1980).
	Dworkin et al., Dietary Intake in Patients with Acquired Immunodeficiency Syndrome (AIDS), Patients with AIDS-Related Complex, and Serologically Positive Human Immunodeficiency Virus Patients: Correlations with Nutritional Status, <i>Journal of Parenteral and Enteral Nutrition</i> , 14:605-609 (1990).
	Farmer et al., Speculations on the Design of Nonpeptidic Peptidomimetics, <i>TIPS</i> , 4:362-365, (1982).
	Frohman et al., Rapid Production of Full-Length cDNAs From Rare Transcripts: Amplification Using a Single Gene-Specific Oligonucleotide Primer, <i>Proceedings of the National Academy of Sciences</i> , 85:8998-9002 (1988).
	Galfrè et al., Rat x Rat Hybrid Myelomas and A Monoclonal Anti-Fd Portion of Mouse IgG, <i>Nature</i> , 277:131-133 (1979).
	Gorman et al., Reshaping a Therapeutic CD4 Antibody, <i>Proceedings of the National Academy of Sciences</i> , 88:4181-4185 (1991).
	Hammond et al., Respiratory Muscle Strength in Congestive Heart Failure, <i>Chest</i> , 98:1091-1094 (1990).
	Hardman et al., <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i> , 9 <sup>th</sup> ed., McGraw-Hill Co. (USA), pp. 1528-1529 (1995).
	Hardman et al., <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i> , 9 <sup>th</sup> ed., McGraw-Hill Co. (USA), pp. 1523-1524 (1995).
	Hardman et al., <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i> , 8 <sup>th</sup> ed., McGraw-Hill Co. (USA), pp. 3-32 (1990).

MAR 18 2003

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	04853.0085	Appln. No.	10/019,501
Applicant	Etsuro OGATA et al.		
Filing Date	December 31, 2001	Group:	1646

RECEIVED  
MAR 19 2003  
TECH CENTER 1600/2800

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Harris et al., Therapeutic Antibodies - The Coming of Age, <i>TIBTECH</i> , 11:42-44 (1993).
	Ikeda, Molecular Biology of Parathyroid Hormone-Related Peptide, <i>Nihon Rinshou</i> , 53:37-45 (1995) (English Abstract).
	Ikeda, Development of Novel Endocrinotherapy Targeting Cancer and Paraneoplastic Syndromes, <i>Progress in Clinical Pharmacology</i> , 16:155-161 (1995) (English Abstract).
	Jones et al., Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions, <i>Bio/Technology</i> , 9:88-89 (1991).
	Jüppner et al., A G Protein-Linked Receptor for Parathyroid Hormone and Parathyroid Hormone-Related Peptide, <i>Science</i> , 254:1024-1026 (1991).
	Kaji et al., Role of Dual Signal Transduction Systems in the Stimulation of Bone Resorption by Parathyroid Hormone-Related Peptide, The Direct Involvement of cAMP-Dependent Protein Kinase, <i>Horm. Metab. Res.</i> , 25:421-424 (1993).
	Kajimura et al., Toxohormones Responsible for Cancer Cachexia Syndrome in Nude Mice Bearing Human Cancer Cell Lines, <i>Cancer Chemother Pharmacol</i> , 38:S48-S52 (1996).
	Karlsson et al., Kinetic Analysis of Monoclonal Antibody-Antigen Interactions with a New Biosensor Based Analytical System, <i>Journal of Immunological Methods</i> , 145:229-240 (1991).
	Kato et al., Incisor Change Induced by Excessive PTHrP in Rats, Abstracts of 16 <sup>th</sup> Meeting of Japanese Society of Toxicologic Pathology, p. 17 (2000) (English Translation).
	Kearney et al., A New Mouse Myeloma Cell Line That Has Lost Immunoglobulin Expression But Permits the Construction of Antibody-Secreting Hybrid Cell Lines, <i>The Journal of Immunology</i> , 123:1548-1550 (1979).
	Kemp et al., Parathyroid Hormone-Related Protein of Malignancy: Active Synthetic Fragments, <i>Science</i> , 238:1568-1570 (1987).
	Kettleborough et al., Humanization of a Mouse Monoclonal Antibody by CDR-Grafting: The Importance of Framework Residues on Loop Conformation, <i>Protein Engineering</i> , 4:773-738 (1991).
	Köhler et al., Derivation of Specific Antibody-Producing Tissue Culture and Tumor Lines by Cell Fusion, <i>European Journal of Immunology</i> , 6:511-519 (1976).
	Kozak, At Least Six Nucleotides Preceding the AUG Initiator Condon Enhance Translation in Mammalian Cells, <i>Journal of Molecular Biology</i> , 196:947-950 (1987).
	Kukreja et al., Tumor Resection and Antibodies to Parathyroid Hormone-Related Protein Cause Similar Changes on Bone Histomorphometry in Hypercalcemia of Cancer, <i>Endocrinology</i> , 127(1):305-310 (1990).
	Kukreja et al., Antibodies to Parathyroid Hormone-Related Protein Lower Serum Calcium in Athymic Mouse Models of Malignancy-Associated Hypercalcemia Due to Human Tumors, <i>The Journal of Clinical Investigation</i> , 82:1798-1802 (1988).

MAR 18 2003



OMB No. 0651-0011

## INFORMATION DISCLOSURE CITATION

RECEIVED  
MAY 19 2003  
TECH CENTER 1600/2800

Atty. Docket No.	04853.0085	Appln. No.	10/019,501
Applicant	Etsuro OGATA et al.		
Filing Date	December 31, 2001	Group:	1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Liu et al., Developmental Role of PHTRP in Murine Molars, <i>European Journal Oral Sciences</i> , 106 (suppl 1):143-146 (1998).
LoBuglio et al., Mouse/Human Chimeric Monoclonal Antibody in Man; Kinetics and Immune Response, <i>Proceedings of the National Academy of Sciences</i> , 86:4220-4224 (1989).
Lundgren et al., Parathyroid Hormone (1-34) Receptor-Binding and Second-Messenger Response in Rat Incisor Odontoblasts, <i>Calcif. Tissue Int.</i> , 62:255-259 (1998).
Maeda et al., Construction of Reshaped Human Antibodies with HIV-Neutralizing Activity, <i>Human Antibodies and Hybridomas</i> , 2:124-134 (1991).
Margulies et al., Somatic Cell Hybridization of Mouse Myeloma Cells, <i>Cell</i> , 8:405-415 (1976).
Marosi et al., Fatal Encephalitis in a Patient with Chronic Graft-Versus Host Disease, <i>Bone Marrow Transplantation</i> , 6:53-57 (1990).
Mizushima et al., pEFBOS, A Powerful Mammalian Expression Vector, <i>Nucleic Acids Research</i> , 18:5322 (1990).
Morimoto, PTH/PTHrP, <i>Clinical Calcium</i> , 5(12):50-54 (1995) (English Translation).
Moseley et al., Parathyroid Hormone-Related Protein Purified from A Human Lung Cancer Cell Line, <i>Proceedings of the National Academy of Sciences</i> , 84:5048-5052 (1987).
Mountain et al., Engineering Antibodies for Therapy, <i>Biotechnol Genet Eng Rev.</i> , 10:1-142 (1992).
Muller et al., Überwachung und Handhabung von Zentrainervosen und Intestinalen System zur Behandlung der Tumorkachexie, <i>Langenbecks Arch Chir Suppl II</i> , pp. 261-265 (1990) (English Abstract).
Mulligan et al., Synthesis of Rabbit β-globin in Cultured Monkey Kidney Cells Following Infection with a SV40 β-globin Recombinant Genome, <i>Nature</i> , 277:108-114 (1979).
Natsume et al., Binding Assay and Analysis of Kinetic Parameters by Bialcore Biosensor, <i>Experimental Medicine</i> , 13:85-91 (1995) (English Translation).
Ogata, Parathyroid Hormone-Related Protein as a Potential Target of Therapy for Cancer-Associated Morbidity, <i>Cancer</i> , 88:2902-2911 (2000).
Ohtomo et al., Humanization of Mouse ONS-M21 Antibody with the Aid of Hybrid Variable Regions, <i>Molecular Immunology</i> , 32:407-416 (1995).
Olstad et al., Expression and Characterization of a Recombinant Human Parathyroid Partial Agonist with Antagonistic Properties: Gly-hPTH(-1→+84), <i>Peptides</i> , 16:1031-1037 (1995).
Palmieri et al., Muscle Calcium Accumulation in Muscular Dystrophy, Intracell. Calcium Regul., <i>Proc. Int. Symp.</i> , pp. 335-347 (1986).
Philbrick et al., Parathyroid Hormone-Related Protein is Required for Tooth Eruption, <i>Proc. National Academy of Science USA</i> , 95:11846-11851 (1998).
Queen et al., A Humanized Antibody that Binds to the Interleukin 2 Receptor, <i>Proc. National Academy of Science USA</i> , 86:10029-10033 (1989).

MAR 18 2003

OMB No. 0651-0011

## INFORMATION DISCLOSURE CITATION

Atty. Docket No. JAPAN-0085

Appln. No. 10/019,501

Applicant Etsuro OGATA et al.

Filing Date December 31, 2001

Group: 1646

RECEIVED  
TECH CENTER 1600/2800  
MAR 10 2003

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Riechmann et al., Reshaping Human Antibodies for Therapy, <i>Nature</i> , 332:323-327 (1988).
	Roe et al., A Photometric Method for the Determination of Insulin in Plasma and Urine, <i>Journal of Biological Chemistry</i> , 173:839-845 (1949).
	Rosen et al., The Effect of PTH Antagonist BIM-44002 on Serum Calcium and PTH Levels in Hypercalcemic Hyperparathyroid Patients, <i>Calcified Tissue International</i> , 61:455-459 (1997).
	Roubini et al., Synthesis of Fully Active Biotinylated Analogs of Parathyroid Hormone and Parathyroid Hormone-Related Protein as Tools for the Characterization of Parathyroid Hormone Receptors, <i>Biochemistry</i> , 31:4026-4033 (1992).
	Sato et al., Passive Immunization with Anti-Parathyroid Hormone-Related Protein Monoclonal Antibody Markedly Prolongs Survival Time of Hypercalcemic Nude Mice Bearing Transplanted Human PTHrP-Producing Tumors, <i>Journal of Bone and Mineral Research</i> , 8:849-860 (1993).
	Sato et al., Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell Growth, <i>Cancer Research</i> , 53:851-856 (1993).
	Sato et al., A Highly Sensitive Bioassay for PTH Using ROS 17/2.8 Subclonal Cells, <i>Acta Endocrinologica</i> , 116:113-120 (1987).
	Sato, Malignancy-associated Hypercalcemia: Pathogenesis and Treatment, <i>Journal of Tokyo Women's Medical College</i> , 58(9):939-946 (1988) (English Abstract).
	Saito et al., Potential Involvement of PTHrP in Cancer Cachexia, <i>Japanese Journal of Cancer Research</i> , 90 (Suppl.): Abstract No. 2195 (1999) (English Abstract).
	Shigeno, PTH/PTHrP Receptor, <i>Clinical Calcium</i> , 5(3):79-83 (1995) (English Translation).
	Shulman et al., A Better Cell Line for Making Hybridomas Secreting Specific Antibodies, <i>Nature</i> , 276:269-270 (1978).
	Stewart et al., Clinical Review 16: Parathyroid Hormone-Related Proteins: Coming of Age in the 1990s, <i>Journal of Clinical Endocrinology and Metabolism</i> , 71:1410-1414 (1990).
	Strewler, The Physiology of Parathyroid Hormone-Related Protein, <i>The New England Journal of Medicine</i> , 342(3):177-185 (2000).
	Sumiya et al., Hypercalcemia with Malignant Tumor, <i>Saishin Igaku</i> , 46(2):315-324 (1991) (English Abstract).
	Suva et al., A Parathyroid Hormone-Related Protein Implicated in Malignant Hypercalcemia: Cloning and Expression, <i>Science</i> , 237:893-896 (1987).
	Takahashi et al., Structure of Human Immunoglobulin Gamma Genes: Implications for Evolution of a Gene Family, <i>Cell</i> , 29:671-679 (1982).
	Takahashi et al., Concentrations of Blood Parathyroid Hormone Related Protein (PTHrP) and Various Cytokines in Malignant Tumor Patients, <i>Record of the Japan Society of Clinical Biochemistry and Metabolism</i> , 35:107 (1998) (English Abstract).
	Tanaka, Triple Paraneoplastic Syndrome of Hypercalcemia, Leukocytosis and Cachexia in Two Human Tumor Xerografts in Nude Mice, <i>Japanese Journal of Clinical Oncology</i> , 26:88-94 (1996).

MAR 18 2003

OMB No. 0651-0011

## INFORMATION DISCLOSURE CITATION

RECEIVED  
MARCH 19 2003  
TECH CENTER 1000/2000

Atty. Docket No. 1453.0085	Appn. No. 10/019,501
Applicant Etsuro OGATA et al.	
Filing Date December 31, 2001	Group: 1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Tempest et al., Reshaping A Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection <i>in vivo</i> , <i>Bio/Technology</i> , 9:266-271 (1991).
	Tenorio et al., An Immunohistochemical Investigation of the Expression of Parathyroid Hormone Receptors in Rat Cementoblasts, <i>Archs Oral Biol.</i> , 41:299-305 (1996).
	Tisdale et al., Cancer Cachexia, <i>International Journal of Pancreatology</i> , 7:141-150 (1990).
	Trowbridge, Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200, <i>Journal of Experimental Medicine</i> , 148:313-323 (1978).
	Verhoeven et al., Reshaping Human Antibodies; Grafting an Antilysozyme Activity, <i>Science</i> , 239:1534-1536 (1988).
	Weissglas et al., Hypercalcemia and Cosecretion of Interleukin-6 and Parathyroid Hormone Related Peptide by a Human Renal Cell Carcinoma Implanted into Nude Mice, <i>The Journal of Urology</i> , 153:854-857 (1995).
	Wong et al., Modulation of Antibody Affinity by an Engineered Amino Acid Substitution, <i>J. Immunol.</i> , 154(7):3351-8 (1995).
	Yamamoto et al., Parathyroid Hormone-Related Peptide-(1-34) [PTHRP-(1-34)] Induces Vasopressin Release from the Rat Supraoptic Nucleus <i>in Vitro</i> through a Novel Receptor Distinct from a Type I or Type II PTH/PTHRP Receptor, <i>Endocrinology</i> , 138:2066-2072 (1997).
	Yelton et al., Fusion of Mouse Myeloma and Spleen Cells, Lymphocyte Hybridomas, Second Workshop on "Functional Properties of Tumors of T and B Lymphocytes," Sponsored by the National Cancer Institute (NIH) 1-7 (1978).
	Yoshida et al., Study of Abnormal Calcium Level in Myotonic Dystrophy-Part II: with Respect to Nephrogenous Cyclic AMP and Immunoreactivity of Serum Parathyroid Hormone, <i>The Japanese Endocrine Society Endocrine Journal</i> , 64(7):539-547 (1988) (English Abstract).
	Zylicz et al., Metabolic Response to Enteral Food in Different Phases of Cancer Cachexia in Rats, <i>Oncology</i> , 47:87-91 (1990).

Examiner	Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

**PLEASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:**

In Re Application of: OGATA et al.

Application No.: 10/019,501

PCT Filing Date: July 3, 2000

§ 371 Date: December 31, 2001

For: AGENT FOR AMELIORATING LOW VASOPRESSIN LEVEL

1. Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(b) (2 pages)
2. Form PTO 1449 (7 pages) with 123 references

Dated: March 18, 2003

Docket No.: 04853.0085-00000

(Due Date: N/D/D)

Atty/sec: RMM/AEPurcell

*Please return PTOcard P. Hervey@MD680*

